Parkinson's future

$2.4 million has been awarded to nine research teams to validate nine promising therapeutic targets in Parkinson's disease. To attract an industry sponsor with the resources and expertise to chaperone any new therapeutic requires a critical mass of evidence. This award could help any one of the nine teams bring a target to the point where optimization, preclinical work and ultimately clinical testing, will be viable. Projects funded in this cohort of Target Validation awardees fall into three categories: targets for therapies to alleviate symptoms of PD; approaches focused on dyskinesias, the excessive, uncontrollable movements brought on by long-term dopamine replacement therapy; and targets with potential to slow or stop progression of Parkinson's.